HIMS
Hims & Hers Health, Inc.

Hims & Hers Health, Inc.HIMS

Healthcare · Drug Manufacturers - Specialty & Generic
27.99USD
+0.36%
Sep 23, 2026
HIMS overview ready
Direct-to-consumer telehealth platform expanding digital obesity care access
Direct-to-consumer telehealth platform that connects patients with licensed providers and facilitates ongoing obesity-treatment access, including FDA-approved GLP-1 options alongside digital care and fulfillment workflows.
Direct narrative exposure
Exposed to the Metabolic Disease Treatment Expansion narrative through Digital Obesity Care and Access Navigation — enabling supplier.
Price trend is broken
Longer-term context reads new trend, with a near-term setup of failed reclaim.
The tactical setup reads failed reclaim, but the weekly structure is broken.
Demanding valuation
The price embeds expectations that run ahead of the cash the business currently produces.
Unremarkable fundamentals
Primary risk
Regulatory changes impacting telehealth and prescription drug sales.
Market Sep 18Filing Jun 30Price action Aug 7Research Aug 7

Conviction Level

NarrativeHeat5.8ThemeHeat5.0PriceAction2.0Valuation2.4CompanyPosition9.3
Price
Loading price history…

Price Action

Price trend is broken
Longer-term context reads new trend, with a near-term setup of failed reclaim.
The tactical setup reads failed reclaim, but the weekly structure is broken.

Key Financials

Market Cap
$6.3B
Avg Volume (60D)
17.8M
60 sessions
Revenue Growth YoY
+59.0%
FY2025 vs FY2024
Gross Margin
+68.4%
Trailing twelve months
Operating Margin
-6.0%
Trailing twelve months
Free Cash Flow Yield
+1.9%
Next Earnings
2026-11-09
P/E
48.1x
EV / Sales
2.7x
Market metrics as of Sep 18, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Fundamentals & Valuation

Both valuation perspectives agree this company is expensive.
Hims & Hers Health, Inc. has an Expensive valuation stance because the price embeds expectations that run ahead of the cash the business currently produces. It trades at 2.7x revenue, which requires sustained delivery to be justified.

What changed

  • HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
    Dated 2026-09-02.
    2026-09-02 · source
  • Hims & Hers Health (HIMS) Is Down 14.6% After Raising Guidance Amid Privacy Scrutiny - What's Changed
    Dated 2026-08-29.
    2026-08-29 · source
  • Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks
    Dated 2026-08-27.
    2026-08-27 · source

Company Research

Thesis
Direct-to-consumer telehealth platform that connects patients with licensed providers and facilitates ongoing obesity-treatment access, including FDA-approved GLP-1 options alongside digital care and fulfillment workflows.
Opportunity
Moderate opportunity
Consumer demand and healthcare-system efforts to widen convenient, affordable access to obesity medicines and longitudinal metabolic-care support through digital care platforms.
Key risk
Regulatory changes impacting telehealth and prescription drug sales.

Narrative & Theme

Metabolic Disease Treatment Expansion
Part of Digital Obesity Care and Access Navigation, with strong fit.
HIMS is a direct participant in the active digital-obesity-access theme, not merely a healthcare-sector adjacency: its weight-loss membership, clinician access, consumer acquisition and care-navigation workflows are designed to convert obesity-treatment demand into recurring platform revenue.
Narrative HeatNeutral5.8 / 10
Theme HeatNeutral5.0 / 10

Business & Markets

Healthcare · Drug Manufacturers - Specialty & Generic
What they do

Hims & Hers Health, Inc. operates a consumer-first digital health and wellness platform that connects customers with licensed healthcare professionals and offers health products through its websites and mobile app across multiple countries.

How it earns

The company generates revenue primarily through direct-to-consumer transactional sales of prescription and non-prescription health and wellness products and services.

Products & services
Prescription health products
Non-prescription health and wellness products
Over-the-counter drugs and devices
Cosmetics
Supplements
Customers & end markets
Individual consumers in the United States
Individual consumers in international markets including the UK, Canada, Germany, Ireland, France, and Spain
Market position

Niche player focused on direct-to-consumer digital health and wellness services with a growing international presence.

Demand drivers
Low cyclicality

Demand for healthcare and wellness products tends to be stable and less sensitive to economic cycles.